** Medical device maker Medtronic's MDT.N shares rise 1% to $90.86
** U.S. FDA has approves co's deep brain stimulation system $(DBS)$ for use in patients with Parkinson's disease
** DBS uses a surgically implanted device called neurostimulator to send electrical signals to specific parts of the brain that have been affected by the neurological disorder
** The system adjusts the therapy to each person's brain activity in real time
** The tech will be available to Parkinson's patients who have been previously implanted with a neurostimulator, as well as future DBS patients - co
** Patient programmings in the United States will begin at select healthcare systems over the coming weeks with availability nationwide in the coming months - MDT
** MDT rose 4.7% in the last 12 months
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.